An Extension Study of LON002 in Patients With Cancer
The purpose of this clinical trial is to evaluate the long term safety and efficacy of LON002.
Solid Tumours
DRUG: LON002
Proportion of patients with Adverse Events grade â‰¥3 related to LON002 and Serious Adverse Events related to LON002 as a measure of safety and tolerability., Participants will be followed for the duration of their study treatment, an expected average of 6 months
This is an extension study of LON002 in patients with cancer, who have completed other London Pharma sponsored LON002 studies (parent study). It provides the opportunity for patients to continue receiving treatment for as long as the patient continues to derive a clinical benefit.

Long term safety and efficacy will be evaluated.